The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 5 Challenges in the Treatment & Diagnosis of Lupus

5 Challenges in the Treatment & Diagnosis of Lupus

February 13, 2020 • By Kelly Tyrrell

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Ovchinnkov Vladimir / shutterstock.com

Ovchinnkov Vladimir / shutterstock.com

A recent study published in Lupus Science & Medicine lays out five of the top barriers impeding progress in lupus diagnosis and treatment.1

You Might Also Like
  • 2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • Atacicept Shows Promise in Lupus Treatment Trials
Explore This Issue
February 2020
Also By This Author
  • New RheumPAC Chair Zachary Wallace, MD, MSc, Promotes a Louder Voice for Rheumatology

The Addressing Lupus Pillars for Health Advancement project (ALPHA), led by the Lupus Foundation of America (LFA), researchers at the Tufts School of Medicine Center for the Study of Drug Development (Tufts CSDD) and 13 international lupus experts representing the Global Advisory Committee, serves as the first global consensus on key issues in lupus.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We cast the net very widely, thinking about where we are with lupus diagnostic delays, treatment options, access to care, clinical trials, and clinical and basic research—everything people with lupus are facing every day,” says senior author Karen Costenbader, MD, MPH, director of the lupus program at Brigham and Women’s Hospital, Boston, professor of medicine at Harvard Medical School, Boston, and chair of the LFA Medical-
Scientific Advisory Council. “Our key finding was that, of all the barriers, heterogeneity of the disease is among the primary, [because] it cuts across drug development, clinical care and access to care.”

In fact, respondents to the survey developed by the ALPHA project identified 30 diseases or disease terminologies related to lupus, reflecting a lack of consensus as to what constitutes the disease. Lupus nephritis, cutaneous lupus and antiphospholipid antibody syndrome were most commonly cited under the “lupus umbrella.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“There are many different kinds of lupus—lupus that affects only the skin or only blood cells or only the brain,” says Dr. Costenbader. “Sometimes, it is labeled incomplete lupus or mixed connective tissue disease or undifferentiated connective tissue disease. The jargon gets people confused and, [although] we didn’t come to firm conclusions, it [may be] the first time people [were] thinking about what does and doesn’t go under the umbrella of lupus.”

For the study, the LFA and Tufts CSDD together identified criteria to establish the Global Advisory Committee, a geographically diverse group of professionals and thought leaders from industry, academia and patient advocacy. The committee brainstormed and formulated a list of barriers, developed in part by conducting 17 in-depth interviews with lupus professionals and patients. They conducted 127 surveys with experts in 20 countries to “prioritize the barriers and nail down what they are,” Dr. Costenbader says. “I think the results will be very useful in thinking about the road map to get resources to address barriers; here are what are the most challenging and here are the easiest to address.”

The survey included 23 questions and asked participants to rank the primary obstacles to lupus diagnosis, treatment, research and care according to their relative impact on delayed drug development, suboptimal clinical care, delayed access to care and inaccurate or delayed diagnoses, and to identify lupus-related disorders.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The top five barriers identified by ALPHA are:

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Research Reviews, SLE (Lupus) Tagged With: Access to care, adherence, Biomarkers, clinical trials, heterogeneity, SLE Resource Center, Socioeconomic ImpactIssue: February 2020

You Might Also Like:
  • 2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • Atacicept Shows Promise in Lupus Treatment Trials
  • Research Targets Interferon Alpha in New Treatment Approach for CNS Lupus

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)